Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgeryContinue reading
Author Archive: AZBio
EPVSensors Takes a Closer Look at Glaucoma
UA-developed technology may lead to a breakthrough in glaucoma detection and treatment.Continue reading
AZBio honors Lynn Hudson, Ph.D., Chief Science Officer of the Critical Path Institute, as the 2015 Arizona Bioscience Leader
Citing her leadership in advancing extremely complex biomedical research, the Arizona Bioindustry Association today announced that Lynn Hudson, Ph.D., Chief Science Officer for the Critical Path Institute, will be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award, during ceremonies later this year.Continue reading
The Start of SynCardia Total Artificial Heart Destination Clinical Study Wins Edison Awards’ Top Honor
Gold Award recognizes the FDA approval of a study into the effectiveness of the SynCardia Total Artificial Heart powered by the Freedom® portable driver for end-stage biventricular heart failure patients who don’t qualify for donor heart transplants.Continue reading
SynCardia Systems, Inc. files Form S-1 for IPO
“SynCardia Systems, a developer and manufacturer of temporary implantable artificial hearts, filed on Monday with the SEC to raise up to $40 million in an initial public offering.” (Source) Continue reading
Opportunity Alert- Apply to NCATS for SBIR STTR Funding
The National Center for Advancing Translational Sciences (NCATS) has several open funding opportunities available for small businesses interested in commercializing translational technologies.Continue reading
Blackstone Ventures to acquire Lattice Biologics
Blackstone Ventures Inc. (TSX VENTURE:BLV) has entered into a letter of intent, subject to receipt of all applicable regulatory and shareholder approvals, to acquire Lattice Biologics Inc.Continue reading
DxNA LLC opens Valley Fever multicenter clinical trial
Rapid, accurate test for coccidioidomycosis developed by TGen’s Pathogen Genomics Division to accelerate patient careContinue reading
Mayo Clinic-led study validates tool for pt. reporting side effects in cancer clinical trials
PHOENIX — A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute’s Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology.Continue reading